It was recently announced that Heberprot-P, a recombinant epidermal growth factor developed in Cuba, has been approved by the US FDA for the biotechnology company Discovery Therapeutics Caribe (DTC) to conduct a Phase III study of the drug in...
It was recently announced that Heberprot-P, a recombinant epidermal growth factor developed in Cuba, has been approved by the US FDA for the biotechnology company Discovery Therapeutics Caribe (DTC) to conduct a Phase III study of the drug in...
It was recently announced that...